{"preliminary_commentary":{"by_channel":{"x_thread":34,"youtube":4,"x_video":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06100874\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"SATEEN","nct_id":"NCT06100874","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sateen-nct06100874. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will complete the following:\n\n* Baseline visit with assessments.\n* CT or MRI scans every 9 weeks for 27 weeks and then every 12 weeks.\n* Echocardiogram or MUGA scan every 12 weeks for 24 weeks and then every 16 weeks.\n* Cycle 1 through Cycle 2:\n\n  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.\n* Cycle 2:\n\n  * Day 1: Optional tumor biopsy\n  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.\n* Cycle 3 through End of Treatment:\n\n  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.\n* End of treatment:\n\n  * Follow up visits every 6 months.","label":"Sacituzumab Govitecan + Trastuzumab (or Biosimilar)","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences"],"completion_date":{"date":"2027-11-30","type":"ESTIMATED"},"conditions":["Her 2 Positive Breast Cancer","Breast Cancer Female","Breast Cancer Metastatic"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan","otherNames":["Trodelvy"],"type":"DRUG"},{"name":"Trastuzumab","otherNames":["Herceptin"],"type":"DRUG"},{"name":"Trastuzumab and Hyaluronidase-oysk","otherNames":["Herceptin Hylecta"],"type":"DRUG"}],"last_update":"2026-02-24","lead_sponsor":"Adrienne G. Waks","official_title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-02-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR)","timeFrame":"3 years"}],"references":[],"start_date":{"date":"2023-11-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","url":"https://clinicaltrials.gov/study/NCT06100874"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sateen-nct06100874"}